Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

Pharmaceutical giant Pfizer (NYSE: PFE) is trading near its lowest price in over a decade. The company's revenue and profits ballooned during the pandemic on its COVID-19 vaccine and treatment ...

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

Its financials aren't in bad shape, and while the stock has been struggling, now could mak 3 Reasons Pfizer Stock Could Be a Steal of a Deal in 2025 | Nasdaq Skip to main content ...

Here is whether Pfizer stock might be a buy today -- and why. Pfizer's pandemic boom (and bust) shouldn't haunt the stock much longer. ... the financials backing it remain rock-solid.